Beam Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2024 Annual Meeting of Stockholders held by Beam Therapeutics Inc. on June 5, 2024. The filing details the voting outcomes for director elections, auditor ratification, and executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following proposals were voted upon at the Annual Meeting:
- Proposal 1 (Director Election): Graham Cooper was elected as a Class I director. Votes cast were 49,482,793 For, 6,520,772 Against, and 1,838,647 Abstentions. There were 8,424,668 Broker Non-Votes.
- Proposal 2 (Auditor Ratification): The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. Votes cast were 66,048,930 For, 176,166 Against, and 41,784 Abstentions.
- Proposal 3 (Executive Compensation): The compensation of named executive officers was approved on an advisory basis. Votes cast were 56,501,513 For, 1,295,311 Against, and 45,388 Abstentions. There were 8,424,668 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Confirm the term length for the newly elected director, Graham Cooper, which extends until the 2027 annual meeting.
- Note the significant number of Broker Non-Votes (8,424,668) recorded for the director election and executive compensation proposals.
- Review the Definitive Proxy Statement filed on April 19, 2024, for detailed background on the proposals.